The SYNCHRONIZE-1 trial evaluated survodutide in non-diabetic adults with obesity or overweight with at least 1 weight-related complication.

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in HSCT patients.

Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.

Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.

Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...

No significant drug-related differences seen for clinical pain severity, thermal threshold or tolerance, general pain ...

The new weekly 120mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.

Zanidatamab plus chemotherapy with or without tislelizumab significantly improves progression free survival in first-line ...

Lonvo-z is an in vivo CRISPR gene editing candidate that is designed to inactivate the kallikrein B1 gene, thereby permanently lowering kallikrein and bradykinin levels.

About one-third of children and adolescents use dietary supplements in the US, according to a study published online April 24 in Pediatrics Open Science. Brandy ...